- Conditions
- Diabetes Mellitus Type 2
- Interventions
- aleglitazar+metformin, placebo+metformin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 22
- States / cities
- Chino, California • Hawaiian Gardens, California • Los Angeles, California + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2329–2352
of 7,074
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Sickle Cell Disease
- Interventions
- Placebo, HQK-1001
- Drug
- Lead sponsor
- HemaQuest Pharmaceuticals Inc.
- Industry
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 8
- States / cities
- Madison, Alabama • Oakland, California • Daytona Beach, Florida + 5 more
- Conditions
- HIV-ASSOCIATED NEUROCOGNITIVE DISORDER (HAND)
- Interventions
- LM11A-31, Placebo
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Intermittent Claudication, Peripheral Artery Disease
- Interventions
- Placebo, 375 mg CK-2017357, 500 mg CK-2017357
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Santa Ana, California • Stanford, California + 11 more
- Conditions
- Thyroid Neoplasms
- Interventions
- Sorafenib (Nexavar, BAY43-9006), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Stanford, California • New Haven, Connecticut + 10 more
- Conditions
- Coronary Artery Disease, Overweight
- Interventions
- Salsalate, Placebo
- Drug
- Lead sponsor
- Joslin Diabetes Center
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 5
- States / cities
- York Village, Maine • Boston, Massachusetts • Framingham, Massachusetts + 2 more
- Conditions
- Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris
- Interventions
- secukinumab 300 mg Q4W, secukinumab 300 mg Q2W, Placebo
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Thousand Oaks, California • Cromwell, Connecticut + 12 more
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- Ocrelizumab, Ocrelizumab Placebo, Fingolimod, Fingolimod Placebo
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 10
- States / cities
- La Jolla, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more
- Conditions
- Thromboembolism
- Interventions
- Warfarin, Dabigatran etexilate
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,589 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • Clearwater, Florida • Normal, Illinois + 7 more
- Conditions
- Healthy Volunteers, Pulmonary Arterial Hypertension
- Interventions
- LTP, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 232 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Orange, California • Stanford, California + 16 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Anifrolumab, Placebo
- Biological · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 18 more
- Conditions
- Irritable Bowel Syndrome in Females
- Interventions
- TU-100, Placebo
- Drug
- Lead sponsor
- Tsumura USA
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Tuberculosis, Tuberculosis, Pulmonary
- Interventions
- Sutezolid, Placebo
- Drug
- Lead sponsor
- Global Alliance for TB Drug Development
- Other
- Eligibility
- 19 Years to 50 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Renal Failure, Coronary Artery Disease, Surgery, Surgery-Complications
- Interventions
- CoQ10 1200 mg orally with Glutathione 1000 mg orally, Group B: Placebo CoQ10 orally and Placebo Glutathione orally
- Drug
- Lead sponsor
- George Washington University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Myocardial Infarction (MI), Acute Coronary Syndromes (ACS)
- Interventions
- Cangrelor (P2Y12 inhibitor), clopidogrel (oral P2Y12 inhibitor), Placebo bolus & placebo infusion, Placebo capsules - end of infusion, Placebo capsules - as soon as possible after randomization
- Drug
- Lead sponsor
- The Medicines Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8,882 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Tolerance, Safety Issues, Aging
- Interventions
- Ketone ester, Non-ketone placebo
- Other
- Lead sponsor
- Buck Institute for Research on Aging
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Novato, California
- Conditions
- Esrd
- Interventions
- Ergothioneine, Placebo
- Dietary Supplement · Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Post Traumatic Stress Disorder
- Interventions
- Brexpiprazole, Sertraline, Placebo
- Drug · Other
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Type 1 Diabetes
- Interventions
- Sitagliptin and Lansoprazole, Placebo
- Drug
- Lead sponsor
- Sanford Health
- Other
- Eligibility
- 11 Years to 45 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2015
- U.S. locations
- 3
- States / cities
- San Diego, California • Saint Paul, Minnesota • Sioux Falls, South Dakota
- Conditions
- Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases
- Interventions
- Peresolimab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 491 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Glendale, Arizona + 43 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Tivantinib, Placebo, Cetuximab, Irinotecan
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 24
- States / cities
- Beverly Hills, California • Encinitas, California • Fountain Valley, California + 21 more
- Conditions
- Sleep Initiation and Maintenance Disorders
- Interventions
- zolpidem tartrate, sodium oxybate, Matching Placebos
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Chronic Heart Failure With Preserved Systolic Function
- Interventions
- Dapagliflozin 10Mg Oral Tablet, Dapagliflozin matching placebo
- Drug
- Lead sponsor
- Saint Luke's Health System
- Other
- Eligibility
- 19 Years to 119 Years
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 26
- States / cities
- Fairhope, Alabama • Los Angeles, California • Jacksonville, Florida + 21 more
- Conditions
- Bipolar Disorder I, Bipolar Disorder II, Major Depressive Episode
- Interventions
- SAGE-217, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 11
- States / cities
- Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 8 more